ETON News and Press, Eton Pharmaceutcials Inc. From 04/30/24

- Company anticipates 10-month review for potential approval in Q1 2025 - - Eton expects ET-400 and Alkindi Sprinkle ® to achieve potential combined peak sales of more than $50 million annually - - Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 (GLOB...

2024-04-29 17:00:21 ET Gainers: GeneDx Holdings  ( WGS ) +22% . Zapp Electric Vehicles Group  ( ZAPP ) +8% . Amkor Technology ( AMKR ) +7% . Woodward ( WWD ) +6% . NXP Semiconductors ( NXPI ) +5% . Losers: F5 ( ...

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quar...

2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac  ( CVAC ) +5% . CorMedix  ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...

2024-03-22 03:31:05 ET More on Eton Pharmaceuticals, Relief Therapeutics Holding SA, etc. Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Eton Pharmaceuticals Historical earnings data for Eton Pharmaceuticals ...

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU"...

2024-03-15 10:00:13 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-14 21:38:06 ET Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Results Conference Call March 14, 2024 04:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer C...

2024-03-14 16:10:43 ET More on Eton Pharmaceuticals Seeking Alpha’s Quant Rating on Eton Pharmaceuticals Historical earnings data for Eton Pharmaceuticals Financial information for Eton Pharmaceuticals Read the full article on Seeking Alpha For...

Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 Announce...